PharmAware Blog » Print » Removal of Mixtard30 will be costly and disrupt patient care

Removal of Mixtard30 will be costly and disrupt patient care

Posted By admin On 16/08/2010 @ 05:05 pm In EBM updates | No Comments

Danish drug company Novo Nordisk is to withdraw Mixtard30, a form of insulin used by 90,000 patients in the UK. DTB says this will be costly; if all patients switched to Novo Nordisk’s alternative Novomix30, this would cost the NHS £9M a year.

BMJ 2010; 341: c4210

Article printed from PharmAware Blog: http://pharmawareblog.co.uk

URL to article: http://pharmawareblog.co.uk/2010/08/16/removal-of-mixtard30-will-be-costly-and-disrupt-patient-care/

Click here to print.